Acerus Pharmaceuticals (ASP) Hits New 52-Week Low at $0.13

Acerus Pharmaceuticals Co. (TSE:ASP) shares reached a new 52-week low during trading on Thursday . The company traded as low as C$0.13 and last traded at C$0.13, with a volume of 121360 shares trading hands. The stock had previously closed at C$0.13.

The company has a debt-to-equity ratio of 105.08, a current ratio of 0.69 and a quick ratio of 0.29.

In related news, Director Stephen Robert Gregory acquired 320,000 shares of Acerus Pharmaceuticals stock in a transaction dated Friday, December 7th. The shares were purchased at an average cost of C$0.14 per share, with a total value of C$44,800.00. Insiders have bought 527,700 shares of company stock worth $86,218 over the last ninety days.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/12/08/acerus-pharmaceuticals-asp-hits-new-52-week-low-at-0-13.html.

Acerus Pharmaceuticals Company Profile (TSE:ASP)

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia.

Further Reading: What is a closed-end mutual fund (CEF)?

Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply